Doshi S - Search Results

1

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D. Gibbs JP, et al. Among authors: doshi s. J Clin Pharmacol. 2017 May;57(5):616-626. doi: 10.1002/jcph.840. Epub 2016 Nov 15. J Clin Pharmacol. 2017. PMID: 27861991 Free PMC article. Clinical Trial.

2

Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.

Doshi S, Chow A, Pérez Ruixo JJ. Doshi S, et al. J Clin Pharmacol. 2010 Sep;50(9 Suppl):75S-90S. doi: 10.1177/0091270010377201. J Clin Pharmacol. 2010. PMID: 20881221

3

Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Sutjandra L, et al. Among authors: doshi s. Clin Pharmacokinet. 2011 Dec 1;50(12):793-807. doi: 10.2165/11594240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 22087866

4

Romiplostim dose response in patients with immune thrombocytopenia.

Perez-Ruixo JJ, Green B, Doshi S, Wang YM, Mould DR. Perez-Ruixo JJ, et al. Among authors: doshi s. J Clin Pharmacol. 2012 Oct;52(10):1540-51. doi: 10.1177/0091270011420843. Epub 2011 Dec 13. J Clin Pharmacol. 2012. PMID: 22167563 Clinical Trial.

5

Denosumab dose selection for patients with bone metastases from solid tumors.

Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Pérez-Ruixo JJ. Doshi S, et al. Clin Cancer Res. 2012 May 1;18(9):2648-57. doi: 10.1158/1078-0432.CCR-11-2944. Epub 2012 Mar 6. Clin Cancer Res. 2012. PMID: 22394983

6

Romiplostim dose-response in patients with myelodysplastic syndromes.

Perez Ruixo JJ, Doshi S, Wang YM, Mould DR. Perez Ruixo JJ, et al. Among authors: doshi s. Br J Clin Pharmacol. 2013 Jun;75(6):1445-54. doi: 10.1111/bcp.12041. Br J Clin Pharmacol. 2013. PMID: 23171070 Free PMC article.

7

Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Pérez-Ruixo JJ. Doshi S, et al. Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x. Clin Pharmacokinet. 2013. PMID: 23912564 Review.

8

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.

Zhu M, Doshi S, Gisleskog PO, Oliner KS, Perez Ruixo JJ, Loh E, Zhang Y. Zhu M, et al. Among authors: doshi s. J Pharm Sci. 2014 Jan;103(1):328-36. doi: 10.1002/jps.23763. Epub 2013 Nov 1. J Pharm Sci. 2014. PMID: 24186235

9

Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.

Perez Ruixo JJ, Doshi S, Sohn W, Chow A. Perez Ruixo JJ, et al. Among authors: doshi s. J Clin Pharmacol. 2015 Mar;55 Suppl 3:S85-92. doi: 10.1002/jcph.388. J Clin Pharmacol. 2015. PMID: 25707967 Review.

10

Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model.

Wu L, Mould DR, Perez Ruixo JJ, Doshi S. Wu L, et al. Among authors: doshi s. J Clin Pharmacol. 2015 Oct;55(10):1157-66. doi: 10.1002/jcph.527. Epub 2015 Jul 21. J Clin Pharmacol. 2015. PMID: 25907551 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters